Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02943733 · ClinicalTrials.gov registry record · Phase 1
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02943733 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 18 participants.
The verdict
NCT02943733, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug combination.
Interventions
- DRUG Temozolomide
- DRUG Filgrastim
- DRUG TAS-102
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2017-08-22 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02943733
The ClinicalTrials.gov registry entry for NCT02943733 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT02943733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02943733 about?
NCT02943733 is a clinical study titled "Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs". The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug combination.
What is the current status of trial NCT02943733?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2017-08-22. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT02943733?
The interventions under investigation include: Temozolomide (DRUG), Filgrastim (DRUG), TAS-102 (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT02943733?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.